


## Gefitinib-d<sub>8</sub>

<b>Cat. No.:</b>	HY-50895S		
<b>CAS No.:</b>	857091-32-8		
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>16</sub> D <sub>8</sub> ClFN <sub>4</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	454.95		
<b>Target:</b>	EGFR; Autophagy		
<b>Pathway:</b>	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Autophagy		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

<b>Description</b>	Gefitinib-d <sub>8</sub> is a deuterium labeled Gefitinib. Gefitinib is an EGFR tyrosine kinase inhibitor, with IC <sub>50</sub> of 2-37 nM in NR6wtEGFR cells[1][2].
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 37 nM (Tyr1173 site, in NR6wtEGFR cells), 37 nM (Tyr992 site, in NR6wtEGFR cells)[1]

### REFERENCES

[1]. Pedersen MW, et al. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRVIII. *Br J Cancer*. 2005 Oct 17;93(8):915-23.

[2]. Moasser MM, et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. *Cancer Res*. 2001 Oct 1;61(19):7184-8.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA